A dose finding study of weekly and every-3-week nab-paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 6, 2010, Pages 852-861

  Socinski, Mark A ^a   Manikhas, Georgiy M ^b   Stroyakovsky, Daniil L ^c   Makhson, Anatoly N ^c   Cheporov, Sergey V ^d   Orlov, Sergei V ^e   Yablonsky, Petr K ^f   Bhar, Paul H ^g   Iglesias, Jose ^g  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b City Oncology Dispensary St Petersburg   (Russian Federation)

^c Moscow City Oncology Clinical Hospital 62   (Russian Federation)

^d Yaroslavl City Oncology Center   (Russian Federation)

^e PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^f St Petersburg City Hospital 2   (Russian Federation)

^g Abraxis BioScience   (United States)

Author keywords

Abraxane; Antitumor activity; Nab Paclitaxel; NSCLC; Taxane

Indexed keywords

ALBUMIN; CARBOPLATIN; NANOPARTICLE; PACLITAXEL; ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; ANEMIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; RETROSPECTIVE STUDIES;

EID: 77953150067     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d5e39e     Document Type: Article

References (23)

1. NICE (National Institute for Clinical Excellence). Lung Cancer: the Diagnosis and Treatment of Lung Cancer, Clinical Guideline 24. National Institute for Clinical Excellence, 2005:1-41.
2. Jett JR, Schild SE, Keith RL, et al. Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:266S-276S.
3. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-3218.
4. Lilenbaum RC, Herndon JE II, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005;23:190-196.
5. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
7. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-1268.
8. Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-1598.
9. ACS (American Cancer Society). Lung cancer (NSCLC) Detailed Guide. ACS, 2008;1-61.
10. Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005;23:7785-7793.
11. Blum JL, Savin MA, Edelman G, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007;7:850-856.
12. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-7803.
13. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophorfree, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006;17:1263-1268.
14. Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1074-1080.
15. Rizvi NA, Riely GJ, Azzoli CG, et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 2008;26:639-643.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
17. van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, et al. The use of the Calvert formula to determine the optimal carboplatin dosage. J Cancer Res Clin Oncol 1995;121:478-486.
18. Stinchcombe TE, Socinski MA, Walko CM, et al. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 2007;60:759-766.
19. Allerton JP, Hagenstad CT, Webb RT, et al. A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings. J Clin Oncol 2006;24 (18 S) : 7127.
20. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophorfree, albumin-bound paclitaxel, ABI-007, compared with cremophorbased paclitaxel. Clin Cancer Res 2006;12:1317-1324.
21. Koukourakis MI, Giatromanolaki A, Brekken RA, et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003;63:5376-5380.
22. Hirsch FR, Dziadziuszko R, Varella-Garcia M, et al. First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. J Thorac Oncol 2008;3: S138-S142.
23. Kosacka M, Piesiak P, Porebska I, et al. Cyclin A and Cyclin E expression in resected non-small cell lung cancer stage I-IIIA. In Vivo 2009;23:519-525.